WWDC 2025: Everything Revealed in 10 Minutes
Back
Services & Software
All the news and tips you need to get the most out of services, apps and software you use every day.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 minutes ago
- Yahoo
If You Can Only Buy 1 Cathie Wood Stock in 2025, It Should Be This
Cathie Wood, founder, CEO and chief investment officer of Ark Invest, continues to make headlines for her high-conviction approach to disruptive innovation. Her flagship fund, the Ark Innovation ETF (ARKK), has posted a 52.9% return in the past 52 weeks, reflecting investor confidence. Known for identifying transformational themes early, Wood maintains focused exposure to industries like genomics, autonomous technology, and blockchain. Within this context, Natera (NTRA) has drawn sharp relevance. The company leads in cell-free DNA testing and precision medicine, aligning directly with Ark's long-term thesis. CoreWeave Just Revealed the Largest-Ever Nvidia Blackwell GPU Cluster. Should You Buy CRWV Stock? AMD Is Gunning for Nvidia's AI Chip Throne. Should You Buy AMD Stock Now? The Saturday Spread: Statistical Signals Flash Green for CMG, TMUS and VALE Tired of missing midday reversals? The FREE Barchart Brief newsletter keeps you in the know. Sign up now! For investors seeking a stock that fits the Ark playbook, Natera may represent one of the most fundamentally aligned additions under Wood's current investment lens. Based in Austin, Texas, stands Natera (NTRA), a pioneer in the field of cell-free DNA and genetic testing. The $23.3 billion biotech firm's arsenal includes powerful offerings like Panorama for prenatal screening, Signatera for real-time cancer surveillance, and Prospera, which sharpens the lens on transplant rejection. Over the last three months, the stock has climbed 16.9%, leaving the broader S&P 500 Index's ($SPX) 5.4% gain behind. On May 8, Natera opened the books on its first-quarter, and the results exceeded Wall Street expectations. Investors responded swiftly, with the stock inching up 1.5% the same day. Natera posted $501.8 million in total revenues, a 36.5% year-over-year increase that soared past Wall Street's $443.3 million forecast. Behind those numbers were powerhouse operations. The company processed 855,100 tests during the quarter, up 16.2% year over year. Women's health volumes climbed meaningfully over the fourth quarter, but it was Signatera that stole the spotlight. The personalized, tumor-informed molecular residual disease test reached new heights, recording its highest volume quarter ever. Clinical volumes for Signatera grew 52% year over year, with a sequential gain of roughly 16,005 units over Q4, marking the most significant quarter-on-quarter growth to date. Gross margins landed at 63.1%, reflecting solid cost discipline. Moreover, Natera's net loss narrowed 1% from the year-ago period to $66.9 million. Also, the company managed to trim its loss per share by 10.7% to $0.50, outperforming analysts' projections of a $0.59 loss per share. As for liquidity, the balance sheet remained in good shape. Cash, cash equivalents and restricted cash climbed to $973.8 million, up from $945.6 million on Dec 31, 2024. CEO Steve Chapman has made no secret of the firm's long-term vision. He believes Signatera could ultimately generate over $5 billion in annual revenue, and he emphasized that they are still playing in the shallow end of a much deeper market pool. In a move that reinforced this optimism, Natera has raised its full-year revenue guidance to between $1.94 billion and $2.02 billion. That is a $70 million boost from the midpoint of its earlier outlook, pointing to a 26% year-over-year growth. On the other hand, analysts expect the Q2 2025 loss per share to widen 100% year over year to $0.60. For FY25, the loss per share is projected to increase 37% to $2.10, but FY26 could bring relief, with a forecast 64.8% narrowing to $0.74, hinting that profitability may finally be within reach. Analysts seem to be singing in harmony when it comes to NTRA, marking it with a firm 'Strong Buy' rating. Out of 19 analysts following the stock, 16 have given it an enthusiastic 'Strong Buy' rating, and the remaining three have placed their bets on a 'Moderate Buy.' The average price target of $200.42 represents potential upside of 17.6%. Meanwhile, the Street-High target of $251 hints at a 48% climb from current levels. Such projections do not come lightly and often reflect deep-rooted confidence in future earnings momentum and strategic execution. On the date of publication, Aanchal Sugandh did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
20 minutes ago
- Yahoo
Is Quantum Computing (QUBT) Stock a Buy on This Bold Technological Breakthrough?
Quantum computing stocks are heating up again, offering investors a front-row seat to what could be the next massive tech revolution. Even Nvidia (NVDA) CEO Jensen Huang, once skeptical about near-term adoption, recently said quantum computing was at an 'inflection point,' signaling a dramatic shift from his earlier stance that it was 'decades away.' Companies in this space are finally beginning to move from the research lab to real-world commercialization. Quantum Computing (QUBT) just hit a major milestone in that journey. The company announced the successful shipment of its first commercial entangled photon source to a South Korean research institution. This cutting-edge product is a foundational piece of QUBT's quantum cybersecurity platform, which won a 2024 Edison Award. The shipment not only showcases the company's ability to execute globally, but also underscores growing demand for integrated quantum solutions. CoreWeave Just Revealed the Largest-Ever Nvidia Blackwell GPU Cluster. Should You Buy CRWV Stock? AMD Is Gunning for Nvidia's AI Chip Throne. Should You Buy AMD Stock Now? The Saturday Spread: Statistical Signals Flash Green for CMG, TMUS and VALE Our exclusive Barchart Brief newsletter is your FREE midday guide to what's moving stocks, sectors, and investor sentiment - delivered right when you need the info most. Subscribe today! With real momentum behind it and a clear roadmap ahead, QUBT could be a high-risk, high-reward play for investors looking to capitalize on the coming wave of quantum adoption. Based in Hoboken, New Jersey, Quantum Computing is an integrated photonics company that focuses on the development of quantum machines for both commercial and government markets in the United States. The company specializes in thin-film lithium niobate chips. These chips are central to QUBT's mission of building quantum machines that operate at room temperature and require low power. Valued at $2.7 billion by market cap, QUBT shares have exploded over the past year, soaring more than 3,000%. However, the stock has cooled in 2025, rising just 17.4% year-to-date amid growing skepticism over the commercialization timeline for quantum technology. Following last year's sharp rally, QUBT's valuation has reached nosebleed territory, with a staggering price-sales ratio of 7,475x, far above the sector median. This suggests the stock is extremely overvalued compared to its industry peers. On May 16, Shares of QUBT popped nearly 40% in a single trading session after Quantum Computing reported Q1 results that illustrate both nascent revenue traction and the substantial investments required to advance its quantum photonics roadmap. The company recognized approximately $39,000 in revenue for the quarter, representing a 42.7% year-over-year increase from a similarly low base. However, this figure fell roughly 61% short of consensus forecasts, highlighting the early stage nature of commercial adoption. Gross margin contracted to 33.3% from 40.7% a year earlier, While net income was reported at nearly $17 million or $0.13 per share, beating the estimate of $0.08, it was driven primarily by a non-cash gain on the mark-to-market valuation of warrant-related derivative liabilities. Operating expenses rose to approximately $8.3 million, up from $6.3 million in the year-ago quarter, as the company expanded staffing and advanced its Quantum Photonic Chip Foundry in Tempe, Arizona. The balance sheet remains robust: cash and cash equivalents totaled about $166.4 million with no debt, providing a multi-year runway at current expenditure levels. Revenue divisions are still emerging, with initial sales tied to prototype devices, quantum cybersecurity platforms, and early foundry orders, but detailed segment reporting is limited given the infancy of commercial deployments. Looking ahead, management indicated they expect only modest photonic foundry revenue in the back half of 2025, with revenue likely to accelerate in 2026 as additional customers come online. Earlier this year, Quantum Computing disclosed collaborations with NASA's Langley Research Center and the Sanders Tri-Institutional Therapeutics Discovery Institute. These partnerships were formed to validate their quantum photonic technologies in demanding, real-world settings, removing sunlight noise from space-based LiDAR and enhancing drug discovery workflows. On May 12, Quantum Computing said it has completed its Quantum Photonic Chip Foundry in Tempe, Arizona, positioning it to meet demand in data communications and telecommunications. This facility enables scalable production of entangled photon sources, enhancing QCI's competitive standing against established photonics firms and emerging quantum hardware startups. The foundry's completion transitions R&D toward revenue generation. For now, only a single analyst covers QUBT stock, assigning it a 'Strong Buy' rating with a price target of $22, implying upside of 14%. For investors, QUBT remains a highly speculative stock with unique technology but limited commercial traction. Despite partnerships and bold claims, it lags far behind the commercial sucess of industry giants like International Business Machines (IBM) and Nvidia (NVDA). Without a clear path to profitability or a meaningful share of the market, its lofty valuation is difficult to justify in today's competitive and capital-sensitive environment. Lastly, investors should note that quantum computing stocks often move more on hype than fundamentals, making QUBT a highly speculative bet. On the date of publication, Nauman Khan did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
Yahoo
29 minutes ago
- Yahoo
Company makes game-changing breakthrough that could solve common issue with plant-based food — here's what you need to know
Let's be honest: Plant-based protein doesn't always taste great. Even if you love the idea of eating less meat for your health and the planet, the weird aftertaste of some plant-based meats can be hard to ignore. But that might be about to change. According to FoodNavigator USA, the flavor company T. Hasegawa USA has developed a high-tech, natural flavor that tackles the unpleasant "off" notes of plant proteins such as pea and soy. The whole technology (and science) behind it is pretty impressive. When meat sizzles in a pan or bread gets crispy in the toaster, the Maillard reaction creates craveable aromas and flavors. But plant proteins such as soy and pea don't react the same way during cooking, which can leave them tasting bland or, worse, beany and bitter. If companies want people to go for meat alternatives, there's a need to focus on options that taste good and have pleasant textures. As Mark Webster, vice president of sales and marketing at T. Hasegawa, said, "That is where the headwind is." The T. Hasegawa team tackled this problem by developing a natural flavor technology called Plantreact that increases Maillard reactions — the chemical processes that give so-called browned foods their flavors. This innovation doesn't stop with fake meats. The same flavor solution can also recreate creamy, dairy-like notes in alternative milks and other nondairy products. That's huge for people who love the idea of oat or almond milk but miss the full-bodied taste of cow's milk. Plantreact has been in the works for a while, but it's now ready to hit the market. T. Hasegawa is already working with food brands to roll it out in products. Better flavor means plant-based foods are more enjoyable, which makes it easier for more people to cut back on animal products and reduce pollution, conserve water, and shrink their carbon footprints. This tech is already being explored by plant-based brands looking to improve their products, and it may soon appear in alternative meat and dairy products at your local grocery store. Combined with the work of companies such as Meati and Perfect Day, this kind of innovation helps build a future in which eating more sustainably doesn't mean compromising on taste. Why do you eat plant-based foods? The health benefits It's cheaper It's good for the planet I prefer the taste Click your choice to see results and speak your mind. Join our free newsletter for easy tips to save more and waste less, and don't miss this cool list of easy ways to help yourself while helping the planet.
